CorVel Corporation
CRVLCorVel Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +16.9% against a −31.8% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (5 weeks in) while the P/BV sits at the 6th percentile of its own 5-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, with the the net margin at 12.0%. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
CorVel Corporation trades at $59.1, in a downtrend and 5 weeks into that stage. That is −5.0% against its own 200-day average. It sits at 24% of a 52-week range of $49 to $93. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 5 of stage 4. At $59.1 it trades −5.0% versus its 200-day average and sits at 24% of its 52-week range ($49–$93).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +291% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
CorVel Corporation trades at 7.6× P/BV, near the bottom of its own range — cheaper only 6% of the time. Its long-run median P/BV is 15.5×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 7.6× is near the bottom of its own range — cheaper only 6% of the time, against a long-run median of 15.5× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved −31.8% — price and book moved together, holding the multiple in its range.
The price move, decomposed: over 5y, of the +1.8%/yr price move, ~+12.9%/yr came from book-value growth and ~−11.1 pp from the multiple (compressing). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
CorVel Corporation reads as turning around on its fundamental arc. Turning around — profit growth swung from −39.0% at the trough to +8.3%, a 3-quarter improving streak, ROE slipping at 133.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +6.7% | +10.1% | — | — |
| Profit | +10.0% | −46.5% | — | — |
| EPS | +16.9% | +19.3% | — | — |
| Stock price | −31.8% | −6.0% | +1.8% | +15.1% |
4-Factor Sector Score
43.4/100 — rank 6 of 15 in Insurance Brokers · 76% evidence confidence
CorVel Corporation scores 43.4 out of 100 against the 15 companies it is compared with in Insurance Brokers, ranking 6. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 16.2 + 18.6 + 5.8 + 2.8 = 43.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
CorVel Corporation reported $0.3 B of income in the Mar 26 quarter, +8.7% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 10.2% a year. The last full year, FY26, came in at $1.0 B. The last four reported quarters add to $1.0 B.
FY26 revenue came in at $1.0 B (+6.7% on the year), capping 4 years at 10.2% compound. The latest quarter (Mar 26) printed $0.3 B, +8.7% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +7.9% growth against the decade's 10.2% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.9% over the last 4 quarters against +9.5%/yr over the last 8 — stabilising; TTM profit +8.3% vs −19.4%/yr — accelerating.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
CorVel Corporation's net margin is 12.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 10.0% to 100.0%. The current quarter sits inside that band.
The latest quarter's net margin is 12.0%, −1.0 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 10.0%–100.0%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
CorVel Corporation earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.1 B. The 4-year compound rate is −35.9%. That is 12.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY26 printed $0.1 B (+10.0%), and the 4-year compound rate is −35.9%.
🚨 Why profit moved: revenue contributed +8.7% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +4.7% vs revenue +7.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for CorVel Corporation, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
CorVel Corporation's revenue grew +6.7% in FY26 to $1.0 B, so the book is growing. The latest quarter ran +8.7% year on year. The net margin on that income is 12.0%, −1.0 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY26 revenue was $1.0 B, +6.7% on the year, and the latest quarter ran +8.7% year on year. The net margin on that revenue is 12.0% this quarter (−1.0 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
CorVel Corporation earns a return on equity of 28% in FY26. Its trough over the ladder below was 28% in FY26. On the asset side every $100 of the balance sheet earned about $15.05, which is the return before leverage is applied.
FY26 ROE came in at 28%. On assets, the latest reading is about 15.05% — every $100 the bank deploys earns roughly $15.05 a year. That clears the bar a bank must beat for its book value to compound.
Why: the ROE ladder shows the move; the deposit-cost and provisioning drivers behind it sit below what we hold.
Dividend
CorVel Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
CorVel Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.5% of CorVel Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.5% of the float is sold short, and at typical trading volumes it would take about 4.7 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
CorVel Corporation: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1TWFG, Inc.TWFG | 61.8/100Mixed-positive evidence70% evidence | BREAKING OUT | 25.6/35 Income 25.9% · PAT 65.5% 71% evidence | 15.4/25 ROA 3.2% · ROE 4.6% · GNPA — 68% evidence | 5.8/20 P/BV 3.77× · P/BV÷ROE 0.82 70% evidence | 15.0/20 RS sector 6.1% · RS bench 2.3% · 1Y 6%7 of 12 weeks ahead 70% evidence |
| Exact sum: 25.6 + 15.4 + 5.8 + 15 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2SelectQuote, Inc.SLQT | 51.1/100Mixed-positive evidence70% evidence | ASLEEP | 25.4/35 Income 10.3% · PAT 100% 71% evidence | 14.1/25 ROA 2.5% · ROE 6.6% · GNPA — 68% evidence | 8.6/20 P/BV 0.17× · P/BV÷ROE 0.03 70% evidence | 3.0/20 RS sector -44.6% · RS bench -48.6% · 1Y -61.9%7 of 12 weeks ahead 70% evidence |
| Exact sum: 25.4 + 14.1 + 8.6 + 3 = 51.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -44.6% and the one-year return is -61.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Marsh & McLennan Companies, Inc.MRSH | 48.0/100Mixed-negative evidence60% evidence | TURNING | 17.1/35 Income — · PAT — 26% evidence | 16.3/25 ROA 2.4% · ROE 8.2% · GNPA — 68% evidence | 7.6/20 P/BV 5.25× · P/BV÷ROE 0.64 70% evidence | 7.0/20 RS sector -3.4% · RS bench -6% · 1Y -6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 16.3 + 7.6 + 7 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Brown & Brown, Inc.BRO | 44.2/100Mixed-negative evidence60% evidence | TURNING | 17.8/35 Income — · PAT — 26% evidence | 11.3/25 ROA 1.1% · ROE 2.4% · GNPA — 68% evidence | 7.0/20 P/BV 1.68× · P/BV÷ROE 0.7 70% evidence | 8.1/20 RS sector -12% · RS bench -15.5% · 1Y -24%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 11.3 + 7 + 8.1 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Willis Towers Watson Public Limited CompanyWTW | 44.2/100Mixed-negative evidence60% evidence | TURNING | 15.3/35 Income — · PAT — 26% evidence | 10.4/25 ROA 1% · ROE 2.9% · GNPA — 68% evidence | 4.9/20 P/BV 3.16× · P/BV÷ROE 1.09 70% evidence | 13.6/20 RS sector 2.1% · RS bench -0.8% · 1Y 3.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 10.4 + 4.9 + 13.6 = 44.2 · Decision use: Price leads the evidence: RS versus the benchmark is -0.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6CorVel Corporationthis pageCRVL | 43.4/100Mixed-negative evidence76% evidence | ASLEEP | 16.2/35 Income 7.1% · PAT 9.1% 71% evidence | 18.6/25 ROA 5.2% · ROE 8.7% · GNPA — 68% evidence | 5.8/20 P/BV 7.06× · P/BV÷ROE 0.81 70% evidence | 2.8/20 RS sector -16.6% · RS bench -19.9% · 1Y -31.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 18.6 + 5.8 + 2.8 = 43.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 7Erie Indemnity CompanyERIE | 42.7/100Mixed-negative evidence60% evidence | TURNING | 14.9/35 Income — · PAT — 26% evidence | 17.1/25 ROA 4.8% · ROE 7.8% · GNPA — 68% evidence | 7.2/20 P/BV 5.08× · P/BV÷ROE 0.65 70% evidence | 3.5/20 RS sector -17.2% · RS bench -20.2% · 1Y -31.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 17.1 + 7.2 + 3.5 = 42.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Crawford & CompanyCRD-A | 39.7/100Mixed-negative evidence70% evidence | TURNING | 9.5/35 Income -3.2% · PAT -41.9% 71% evidence | 9.8/25 ROA 1% · ROE 2.9% · GNPA — 68% evidence | 5.4/20 P/BV 2.75× · P/BV÷ROE 0.95 70% evidence | 15.0/20 RS sector 5.8% · RS bench 3.7% · 1Y 37.9%3 of 12 weeks ahead 70% evidence |
| Exact sum: 9.5 + 9.8 + 5.4 + 15 = 39.7 · Decision use: Price leads the evidence: RS versus the benchmark is 3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Arthur J. Gallagher & Co.AJG | 37.8/100Mixed-negative evidence60% evidence | BREAKING OUT | 18.2/35 Income — · PAT — 26% evidence | 8.1/25 ROA 0.6% · ROE 1.4% · GNPA — 68% evidence | 3.8/20 P/BV 2.49× · P/BV÷ROE 1.78 70% evidence | 7.7/20 RS sector -6.9% · RS bench -10.2% · 1Y -14.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 8.1 + 3.8 + 7.7 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Aon plcAON | 37.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 16.6/35 Income — · PAT — 26% evidence | 12.9/25 ROA 1.3% · ROE 6.3% · GNPA — 68% evidence | 3.5/20 P/BV 7.39× · P/BV÷ROE 1.17 70% evidence | 4.7/20 RS sector -4.4% · RS bench -6.7% · 1Y -2.7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 12.9 + 3.5 + 4.7 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Accelerant HoldingsARX | 32.3/100Thin evidence · provisional58% evidence | ASLEEP | 12.7/35 Income 54.2% · PAT -4779.3% 71% evidence | 6.2/25 ROA -0.1% · ROE -0.7% · GNPA — 68% evidence | 9.6/20 P/BV 4.27× · P/BV÷ROE — 10% evidence | 3.8/20 RS sector -22.5% · RS bench -25.5% · 1Y -55.8%4 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 6.2 + 9.6 + 3.8 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Goosehead Insurance, Inc.GSHD | 62.2/100Thin evidence · provisional48% evidence | BREAKING OUT | 21.0/35 Income — · PAT — 26% evidence | 13.3/25 ROA 5.1% · ROE -10.7% · GNPA — 68% evidence | 9.8/20 P/BV -10.27× · P/BV÷ROE — 10% evidence | 18.1/20 RS sector 6.9% · RS bench 1.4% · 1Y -20.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.3 + 9.8 + 18.1 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Neptune Insurance Holdings Inc.NP | 50.5/100Thin evidence · provisional28% evidence | FADING | 16.2/35 Income — · PAT — 26% evidence | 14.5/25 ROA 35.4% · ROE -14.2% · GNPA — 68% evidence | 9.8/20 P/BV -19.45× · P/BV÷ROE — 10% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 16.2 + 14.5 + 9.8 + 10 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14The Baldwin Insurance Group, Inc.BWIN | 48.1/100Thin evidence · provisional48% evidence | BREAKING OUT | 13.6/35 Income — · PAT — 26% evidence | 5.3/25 ROA -0.2% · ROE -4.5% · GNPA — 68% evidence | 9.8/20 P/BV 2.9× · P/BV÷ROE — 10% evidence | 19.4/20 RS sector 8.6% · RS bench 4.5% · 1Y -10.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 5.3 + 9.8 + 19.4 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Ethos Technologies Inc.LIFE | 37.7/100Thin evidence · provisional44% evidence | ASLEEP | 13.1/35 Income 67% · PAT -305.8% 71% evidence | 4.8/25 ROA -30.8% · ROE -42.6% · GNPA — 68% evidence | 9.8/20 P/BV 1.59× · P/BV÷ROE — 10% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 13.1 + 4.8 + 9.8 + 10 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is CorVel Corporation's stock price today?
CorVel Corporation trades at $59.1, −31.8% over the past year. The company is valued at $3.0 B. The stock sits at 24% of its 52-week range of $49–$93, −5.0% versus its 200-day average. On the tape, the price is in a downtrend, 5 weeks in. — as of 5 August 2026.
What were CorVel Corporation's latest quarterly results?
CorVel Corporation reported total income of $0.3 B and net profit of $0.0 B for the Mar 26 quarter. Income rose 8.7% and profit rose 0.0% year on year. Earnings per share were $0.61. The net margin was 12.0%, 1.0 pp lower than a year earlier. — as of 5 August 2026.
What is CorVel Corporation's revenue?
CorVel Corporation reported revenue of $0.3 B in the Mar 26 quarter, +8.7% year on year. For the full FY26 fiscal year, revenue was $1.0 B (+6.7%). Over the last 4 years revenue compounded at 10.2% a year. — as of 5 August 2026.
What is CorVel Corporation's profit?
CorVel Corporation earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.1 B. The net margin ran 12.0% in the latest quarter. — as of 5 August 2026.
What is CorVel Corporation's market cap?
CorVel Corporation's market capitalisation is $3.0 B at a stock price of $59.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is CorVel Corporation's P/BV ratio?
CorVel Corporation trades at a P/BV of 7.6×, at the 6th percentile of its own 5-year range, against a long-run median of 15.5×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does CorVel Corporation pay a dividend?
No — CorVel Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is CorVel Corporation overvalued?
On its own history, CorVel Corporation looks cheap against its own history: its P/BV of 7.6× has been cheaper only 6% of the time in 5 years (long-run median 15.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is CorVel Corporation growing?
The picture is mixed for CorVel Corporation: latest-quarter revenue +8.7% year on year, profit +0.0%, and the the net margin −1.0 pp at 12.0%. The 4-year compound rates are 10.2% (revenue) and −35.9% (profit). The earnings engine currently reads: mixed — as of 5 August 2026.
How is CorVel Corporation performing?
CorVel Corporation is in a downtrend, 5 weeks in. Its latest quarter's income rose 8.7% and profit rose 0.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is CorVel Corporation in?
Turning around — profit growth swung from −39.0% at the trough to +8.3%, a 3-quarter improving streak, ROE slipping at 133.3%. The read comes from the last 12 quarters of growth (revenue growth +7.9% latest, profit growth +8.3% latest, eps growth +16.3% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is CorVel Corporation in an uptrend?
No — the price is in a downtrend (week 5 of stage 4), trading −5.0% versus its 200-day average and at 24% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is CorVel Corporation beating the market?
Not lately — on a trailing-13-week view CorVel Corporation is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +291% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will CorVel Corporation's stock price go up?
This page publishes no price forecast for CorVel Corporation. What it measures instead: the stock price is $59.1, the price is in a downtrend 5 weeks in. Its P/BV of 7.6× sits at the 6th percentile of its own 5-year range. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against CorVel Corporation?
Somewhat — short interest is 3.5% of CorVel Corporation's tradable float, about 4.7 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Is CorVel Corporation's loan book healthy?
We do not hold quarterly loan-book quality numbers for CorVel Corporation, so this page says that plainly. The cleanest available reads are revenue growth (+6.7% in FY26) and the net margin on it (12.0%) — as of 5 August 2026.
Where is CorVel Corporation in its business cycle?
CorVel Corporation's FY26 net margin was 11.5%, against a 5-year band of 10.0%–100.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 12.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the CorVel Corporation story?
The sharpest disagreement: annual EPS moved +16.9% against a −31.8% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is CorVel Corporation a stock worth studying right now?
This is not investment advice. The machine read: CorVel Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.